Expert Interview
Discussing the potential of CD20 as class in treating Multiple Sclerosis with a focus on BRIUMVI, Kesimpta, and Ocrevus
Ticker(s): TGTX, NVS, RHHBYInstitution: WUSTL
- Professor of Neurology and Director of Multiple Sclerosis Clinic at Washington University School of Medicine, St. Louis.
- Currently treats 500 patients with Multiple Sclerosis (3000 MS patients at center).
- Research focuses on the use of MRI sequences to correlate optic nerves, brain and spinal imaging with clinical diseases and to predict long-term outcome of patients with Multiple Sclerosis.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
